Dynamic Healthcare M&A Database

Acquiring Party	China Medical Technologies (NASDQ:CMED), a China-based medical device company that manufactures high intensity focused ultrasound products and advanced in-vitro diagnostic systems.
Transferring Party	The fluorescent in situ hybridization ("FISH") business of Supreme Well Investments Limited and Molecular Diagnostics Technologies Limited
Sector	Medical Devices
Date	March 6, 2007
Analysis FISH is a type of hybridization in which a DNA probe is labeled with fluorescent dye so that it can be seen with a microscope. China Medical intends to develop and commercialize the FISH technology in China for the diagnosis of prenatal and postnatal disorders as well as various cancers through laboratory evaluation and analysis of bodily fluids and tissues. Deal value--$136m with up to additional $40m based on milestones.
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 1Q07